Personalis PE Ratio 2018-2026 | PSNL
Current and historical p/e ratio for Personalis (PSNL) from 2018 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Personalis PE ratio as of May 20, 2026 is 0.00.
| Personalis PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-05-20 | 7.95 | 0.00 | |
| 2026-03-31 | 6.37 | $-1.02 | 0.00 |
| 2025-12-31 | 7.96 | $-0.91 | 0.00 |
| 2025-09-30 | 6.52 | $-0.88 | 0.00 |
| 2025-06-30 | 6.56 | $-1.28 | 0.00 |
| 2025-03-31 | 3.51 | $-1.29 | 0.00 |
| 2024-12-31 | 5.78 | $-1.37 | 0.00 |
| 2024-09-30 | 5.38 | $-1.68 | 0.00 |
| 2024-06-30 | 1.17 | $-1.64 | 0.00 |
| 2024-03-31 | 1.49 | $-1.90 | 0.00 |
| 2023-12-31 | 2.10 | $-2.25 | 0.00 |
| 2023-09-30 | 1.21 | $-2.38 | 0.00 |
| 2023-06-30 | 1.88 | $-2.36 | 0.00 |
| 2023-03-31 | 2.76 | $-2.46 | 0.00 |
| 2022-12-31 | 1.98 | $-2.48 | 0.00 |
| 2022-09-30 | 2.97 | $-2.27 | 0.00 |
| 2022-06-30 | 3.45 | $-2.09 | 0.00 |
| 2022-03-31 | 8.19 | $-1.83 | 0.00 |
| 2021-12-31 | 14.27 | $-1.49 | 0.00 |
| 2021-09-30 | 19.24 | $-1.38 | 0.00 |
| 2021-06-30 | 25.30 | $-1.25 | 0.00 |
| 2021-03-31 | 24.61 | $-1.20 | 0.00 |
| 2020-12-31 | 36.61 | $-1.20 | 0.00 |
| 2020-09-30 | 21.67 | $0.71 | 30.52 |
| 2020-06-30 | 12.97 | $0.76 | 17.07 |
| 2020-03-31 | 8.07 | $0.16 | 50.44 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |